Science · 10 min read ·
The Science of Mitragynine: A Layperson's Guide to Kratom's Active Compound
Mitragynine is the alkaloid responsible for most of kratom's everyday effects — and the molecule that drives most consumer questions about kratom. Here's an accessible look at its discovery, chemical structure, receptor pharmacology, metabolism, and why concentration matters far more than 'how much kratom' you take.
Frequently Asked Questions
- What exactly is mitragynine?
- Mitragynine is an indole alkaloid — a nitrogen-containing organic compound — produced by the kratom tree (Mitragyna speciosa). It is the dominant psychoactive compound in kratom leaf, comprising 60–70% of the total alkaloid content and roughly 1–2% of dried leaf by mass. Pharmacologically it's a partial agonist at mu-opioid receptors with additional activity at adrenergic, serotonin, and other receptor systems — the polypharmacology that produces kratom's distinctive dose-dependent effect curve.
- When was mitragynine discovered?
- Mitragynine was first isolated from kratom leaves by Dutch chemist E. M. Hooper in 1907, and its structure was confirmed by D. Hooper and others in subsequent decades. The full structural characterization, including stereochemistry, was completed in the mid-20th century. Despite this long scientific history, mitragynine remained relatively obscure in Western pharmacology until kratom's commercial expansion in the 2000s drove renewed research interest.
- How does mitragynine compare to morphine?
- Mitragynine is a much weaker mu-opioid receptor agonist than morphine on a per-molecule basis, and notably it's a partial agonist rather than a full agonist. This means mitragynine produces less maximum receptor activation than morphine even at saturating doses — which is one reason it produces a meaningfully different effect profile (less respiratory depression risk at typical doses, dose-dependent shift from stimulation to sedation). 7-hydroxymitragynine, kratom's minor alkaloid, is much more potent at the same receptor — roughly 10–13x morphine — but it's present in only trace amounts in natural leaf.
- What does mitragynine do at receptors other than opioid?
- Three additional receptor systems are well-documented. (1) Alpha-2 adrenergic agonism — produces the alertness and focus effects characteristic of low-dose kratom; similar to compounds like clonidine. (2) Serotonin receptor activity (5-HT2A and 5-HT2C among others) — contributes to mood effects. (3) Calcium channel modulation — likely contributes to the smooth-muscle relaxant effects observed at higher doses. The polypharmacology is part of why kratom's effect profile differs so noticeably from classical opioids despite the shared mu-opioid receptor activity.
- How is mitragynine metabolized in the body?
- Mitragynine is metabolized primarily in the liver via the cytochrome P450 enzyme system (especially CYP3A4 and CYP2D6). One important metabolic product is 7-hydroxymitragynine — meaning that even when you consume natural-leaf kratom with low 7-OH content, your liver produces additional 7-OH from mitragynine. This in-vivo conversion is part of why natural kratom has analgesic effects beyond what the leaf's small 7-OH content would predict. The half-life of mitragynine in humans is approximately 23–24 hours, so the substance accumulates with daily dosing and clears slowly over days.
- Why does mitragynine concentration matter so much?
- Because effects scale with the amount of mitragynine you consume, not the gram-weight of the kratom product. A 5-gram dose of 1.2% mitragynine leaf delivers ~60 mg mitragynine. A 0.5-gram dose of 12% mitragynine extract delivers the same ~60 mg. Same alkaloid load, very different volume. Concentration determines the dose window, the side-effect threshold, and how easy it is to accidentally overshoot. This is why reading the mitragynine percentage on a Certificate of Analysis matters more than any other label feature.